Open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients

This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.

CT.gov Identifier
NCT07367971
EudraCT Identifier
N/A
CTIS:
N/A
Sponsor
Atom Therapeutics Co., Ltd
Collaborator
N/A
Study Contact Information
N/A
Recruiting
Contact Us

Study Details

Diseases
Focal Segmental Glomerulosclerosis
Study Drug
ABP-671 plus allopurinol
Genes
N/A
Study Dates
Jan 2026 - Jul 2026
Sex
Ignored
Age
18 - 75 Years
Inclusion and Exclusion Criteria
Inclusion Criteria:
  • * Adults 18-75 years with clinical diagnosis of gout.
  • * Stable Allopurinol therapy QD for ≥14 days prior to Day 1.
  • * Cohort N: Normal renal function.
  • * Cohort R: Moderate renal impairment.
Exclusion Criteria:
  • Clinically significant hepatic impairment.
  • * History of Allopurinol hypersensitivity.
  • * Pregnancy or breastfeeding.

Protocol Summary

This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.

Study Locations

To view all trial locations, click here

Contact Us About More Information for the Clinical Trial Concierge Service

Natera’s Clinical Trial Concierge Program is comprised of a dedicated team that helps connect providers and patients with appropriate clinical trials. To learn more about a trial offered through this service, please complete the form below.  

Fields marked with asterisk (*) are mandatory.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.